YICHANG, China, Feb. 6, 2026 /PRNewswire/ — Angel Yeast Group (SH600298) recently welcomed 29 employees from Indonesia to its headquarters in Yichang, China, for a six-month structured training program. The initiative is designed to develop a cohort of skilled professionals to support the commissioning and operations of Angel’s Indonesia facility. As the Chinese Lunar New Year approaches, these young Indonesian trainees are not only learning yeast production techniques but are also gaining firsthand exposure to Spring Festival traditions.

In preparation for the holiday, Angel’s Yichang facility has been decorated to mark the Spring Festival. As they stroll through the city, trainees see shopping malls bustling with people buying holiday goods, while traditional folk melodies fill the parks. Aqil, one of the participants, said, “Everyone here is preparing for the celebrations. Amid all the festive excitement, I can truly feel the energy and richness of the culture.” Before joining Angel, Aqil worked at a local technology company. Like many young professionals, he was attracted to companies with a strong international presence. This customized training program is designed to help him transition into his new role, enhance his technical skills, and strengthen cross-cultural collaboration and teamwork. The multinational program officially began on November 26 last year at China Three Gorges University and consists of 20 days of classroom instruction followed by five months of hands-on operational training.

The Angel Indonesia project represents a key milestone in the company’s international expansion. As an integral part of its global growth strategy, the project is expected to help build local industry capabilities, create job opportunities, and strengthen linkages across the broader value chain. The training program aims to encourage participants to adapt proactively to the new environment, engage in meaningful cultural exchange, and develop a solid mastery of both theoretical knowledge and practical skills, laying a strong foundation for the future plant’s safe, stable, and reliable operations.

Setting up a subsidiary in Indonesia will allow Angel to take advantage of local resources, the strategic location, and tariff advantages, accelerating its expansion into neighboring Asian markets. The project, launched in 2025 in south-central Lampung Province, is located next to the joint venture partner’s sugarcane mill. The site is currently under development, with completion and commissioning scheduled for 2027. The project includes a yeast production line with an annual capacity of 20,000 tons, supported by a wastewater treatment facility capable of processing 3,500 tons per day, as well as an organic fertilizer project designed to reduce waste and improve resource efficiency, with an annual output of 20,000 tons. Angel Yeast Indonesia will source large quantities of locally produced molasses, converting by-products into usable inputs while promoting cleaner production practices. Wastewater from yeast production will be treated and converted into organic fertilizer, and fine yeast by-products will be sold as animal feed, supporting local agriculture and livestock farming, while serving as a practical example of circular economy principles.

The Angel Yeast Indonesia plant is a key part of the company’s global manufacturing network. For Angel, global operations extend beyond expanding production capacity; they focus on supporting the local yeast industry through technology transfer and workforce development, while contributing to growth across related value chains and creating employment opportunities. These young trainees are being prepared to become the core team of the Indonesia facility, playing an important role in enabling global operations, industrial collaboration, and cross-cultural engagement.

Source

TOKYO, Feb. 7, 2026 /PRNewswire/ — SIG Service INC. (Headquarters: Chiyoda-ku, Tokyo), the operator of Doorzo, closed 2025 with record-breaking results, driven by its unwavering global vision of becoming “your gateway to Japan.” Over the course of the year, Doorzo further solidified its position as a leading cross-border shopping platform by broadening its international presence, enhancing platform capabilities, and delivering robust growth across core performance indicators.

Supported by a rapidly expanding global user base, Doorzo achieved significant milestones in total sales, international downloads, and cross-border shipments. These achievements highlight the company’s sustained commitment to expanding global access to Japanese products through continuous technological advancement, localization, and logistics excellence.

About “Doorzo” by SIG Service INC.

Established in 2013, Doorzo is a cross-border e-commerce platform that enables international customers to purchase items from Japan’s marketplaces. Accessible via mobile app and web, offering international shipping.

In 2025, Doorzo surpassed ¥80 billion in total sales, reached 6.2 million app downloads, and shipped over 3.6 million parcels to 118 countries, serving users in 180 countries worldwide. Collectively, Doorzo parcels traveled the equivalent of 160,000 trips around the Earth, highlighting the platform’s scale and global logistics capabilities.

On Trustpilot, Doorzo achieved 4.7 stars across almost 1,000 reviews; supported 17 languages and 44 currencies, enabling a seamless shopping experience for users across major global markets. Top destination regions included: the United States, Canada, Australia, Mainland China, the United Kingdom, Hong Kong, Taiwan, Singapore, Malaysia, the Philippines, Mexico, and France.

Community Highlights and Fun Facts

In order to start 2026 closer with its community, Doorzo also shares some of the most interesting fun facts:

• The most expensive item sold on Doorzo is a Pokémon Trainer “Lillie” trading card, whose market price often lands around ¥6 million.
• Most unusual request: a customer asked to place as many “Fragile” labels as possible on a shipment valued at ¥500,000, consisting of a Zimomomo Titan Everybody Knows toy.

Most popular categories in 2025

• Trading Cards (TCG)
• Figures
• Games
• Toys
• Women’s Fashion

Multicultural Staff

Doorzo fosters a multicultural environment. Staff from different countries and languages who are enthusiastic about Japanese Culture.

Looking ahead to 2026, Doorzo will continue to provide more diverse and convenient services to its global users, followed by its consistent global vision of becoming “your gateway to Japan”.

Visit the “Doorzo” website: https://www.doorzo.com/

Company Overview:

SIG Service INC.

Company Name: SIG Service INC.

Akihabara Office: 2-7-1 Kanda-Suda-cho, Chiyoda-ku, Tokyo

Established: December 2013

Source

Research Introduces 577 Epigenetic Mechanism for Asian Skin

SHANGHAI, Feb. 7, 2026 /PRNewswire/ — The IMCAS World Congress 2026, an internationally recognized forum for aesthetic medicine and clinical research, opened on January 31 in Paris. As a global platform supporting collaboration in dermatology, plastic surgery, and aging science, IMCAS facilitates the exchange of interdisciplinary research and clinical best practices. This year, Chinese skincare brand CHANDO participated in the congress by presenting a long-term research outcome: the identification of a novel epigenetic pathway for skin brightening, termed the 4-Butylresorcinol (577) Pigment Management Mechanism. The research presentation reflects the continued engagement of Chinese industry and research organizations in international scientific dialogue on precision skincare.

Global Forum for Scientific Exchange: CHANDO Research Presented at IMCAS

The IMCAS World Congress serves as a professional convening platform for plastic surgeons, dermatologists, and aesthetic practitioners, supporting the dissemination of medical research and clinical innovation at an international level. The event is designed to encourage professional exchange, continuing education, and the sharing of evidence-based technologies across disciplines.

At this year’s congress, which hosted 225 scientific sessions and attracted 21,764 professionals, CHANDO’s research was reviewed through the IMCAS scientific evaluation process. Selected for a keynote presentation in the main forum, CHANDO skin research scientist Dr. Youssef introduced the study titled “Epigenetic Skincare: A Novel Root-Cause Brightening Mechanism of 4-Butylresorcinol (577) via microRNA Regulation in Asian Populations.” The presentation outlined the company’s long-term research approach to the epigenetic factors influencing skin pigmentation in Asian populations.

Decoding the Biology of Asian Skin: A Targeted Research Approach to Brightening

CHANDO’s research focused on three persistent challenges identified through long-term observation of Asian skin characteristics: stubborn dark spots, susceptibility to sallowness, and a fragile barrier that often leads to rebound darkening. While conventional brightening ingredients tend to take a generalized approach, CHANDO directed its research toward underlying biological mechanisms, studying how environmental factors like UV exposure influence gene expression. In his address, Dr. Youssef explained that since 2014, CHANDO has employed high-throughput sequencing and bioinformatics to analyze Asian skin. The team pinpointed a specific microRNA that plays a central role in UV-induced pigmentation by regulating three key enzymes (MITF, TYR, TYRP1) involved in melanin production.

The pivotal finding: CHANDO’s signature ingredient, 4-Butylresorcinol (577), was shown in laboratory and clinical testing to inhibit this microRNA’s abnormal expression, curbing melanin overproduction at its source. This mechanism differentiates 577 from conventional brightening approaches and provides a targeted strategy relevant to post-sun or post-procedure pigmentation management in Asian skin. Notably, the ingredient also demonstrated high tolerability in clinical testing, making it suitable for sensitive skin types prone to irritation. It effectively reduced dark spots and sallowness while minimizing common side effects like redness or rebound pigmentation.[1]

This recognition follows CHANDO’s earlier designation as the “Global 577 Brightening Leader” by Shangpu Group, an independent research organization, based on the ingredient’s technological innovation and commercial impact.[2] The IMCAS presentation represents an additional instance of consumer-facing research from China contributing to international scientific exchange.

A Decade of Science-Based Research for Asian Skin

For over ten years, CHANDO has invested in foundational research focused on the physiological characteristics of Asian skin. The 577 compound represents more than a functional ingredient—it reflects an applied research outcome derived from epigenetic study and skin biology. Today, 577 is integrated into CHANDO’s Cellcrystal Whitening Radiance Series, demonstrating how laboratory research has been translated into consumer skincare applications designed for pigment management at the biological source.

Looking ahead, CHANDO has indicated its intention to continue participating in skin science research, with the goal of supporting clinically evaluated skincare development and ongoing international collaboration.

Notes:

[1] Data from third-party testing. Among 32 subjects aged 18–60 using the Cellcrystal Whitening Radiance Rejuvenating Serum for 4 weeks, instrumental measurement showed a 21.47% reduction in skin melanin and a 34.92% improvement in brightness. Results may vary individually.
[2] Shangpu Group’s research, finalized April 2025, compared global market performance of 577-based facial brightening products (Jan 1–Dec 31, 2024). CHANDO was recognized as the Global 577 Brightening Leader based on market presence, technology, and product influence. 

Source

Sun Life and charity partner join hands to bounce into the Chinese New Year and connect the community through joy

Over 1,000 gift vouchers distributed in celebration of Sun Life’s milestone as it looks ahead to its 135^th anniversary in Hong Kong

HONG KONG, Feb. 6, 2026 /PRNewswire/ — The “Sun Life ‘The Big Bounce’ World Tour – Hong Kong” officially kicked off today at the Great Lawn of the Art Park in the West Kowloon Cultural District. Featuring the Guinness World Record-certified World’s Biggest Bounce House, the event blends sports, music, and anime for a vibrant and joyful Chinese New Year celebration. As title sponsor, Sun Life invited hundreds of students and parents from Yan Chai Hospital-affiliated kindergartens and childcare centers to be among the first to enjoy the bouncing extravaganza.

The ribbon-cutting ceremony at noon marked the official opening of the world’s largest inflatable castle and a range of amusement facilities, kicking off 17 days of bouncing fun. The ceremony was officiated by Adley Low, Chief Client and Marketing Officer at Sun Life Hong Kong Limited and Jeffrey Li, Group President of INCUBASE Studio. 

Adley Low, Chief Client and Marketing Officer of Sun Life Hong Kong Limited, said: “As Sun Life approaches its 135th anniversary next year, we are delighted to see the community’s enthusiasm for our flagship celebratory event, the “Sun Life ‘The Big Bounce’ World Tour – Hong Kong”. Sun Life is committed to promoting health and wellbeing, and we firmly believe that nurturing the healthy development of young people is essential to enhancing community resilience. This event provides families with a joyful space to

play together, and by inviting students and parents from Yan Chai Hospital’s affiliated facilities to be the first to experience the fun, we hope to spread happiness across every corner of the community. We hope this event inspires the public to embrace a healthy and active lifestyle, leaping into the Chinese New Year with us, and bringing more vitality to society.”

Jason Leung, Chief Executive of Yan Chai Hospital Board, expressed his heartfelt gratitude to Sun Life: “Yan Chai is honored to receive the generous donation of tickets for this big event. It provides parents and children from Yan Chai’s kindergartens with a great opportunity to enjoy quality family time together in this joyful environment, creating cherished childhood memories for our children.” 

Furthermore, to celebrate Sun Life’s upcoming 135th anniversary, starting on 9 February, the company is launching a series of online game activities on social media, giving away 1,350 vouchers to the public. For details, please refer to Sun Life’s official social media channels.

The “Sun Life ‘The Big Bounce’ World Tour – Hong Kong” runs from 6 to 22 February 2026 at the Great Lawn of the Art Park in the West Kowloon Cultural District. The event site covers over 100,000 square feet and features four mega inflatable play zones, including the World’s Biggest Bounce House spanning over 16,000 square feet, certified by Guinness World Records; “The Giant”, Hong Kong’s longest inflatable obstacle course stretching over 150 meters; “Sport Slam”, an arena for sports enthusiasts; and the outer-space themed “airSPACE Pink Alien”. The event also offers dedicated daytime family sessions, “After Dark Bigger Kids” sessions, and CantoPop-themed “After Dark Party” sessions.

About Sun Life

Sun Life is a leading international financial services organisation providing asset management, wealth, insurance and health solutions to individual and institutional Clients. Sun Life has operations in a number of markets worldwide, including: Canada, the U.S., the United Kingdom, Ireland, Hong Kong, the Philippines, Japan, Indonesia, India, Mainland China, Australia, Singapore, Vietnam, Malaysia and Bermuda. As of September 30, 2025, Sun Life had total assets under management of $1.62 trillion. For more information, please visit www.sunlife.com.

Sun Life Financial Inc. trades on the Toronto (TSX), New York (NYSE) and Philippine (PSE) stock exchanges under the ticker symbol SLF. Sun Life Financial Inc. is the holding company of Sun Life Assurance Company of Canada. Sun Life Hong Kong Limited (incorporated in Bermuda with limited liability) is a wholly-owned subsidiary of Sun Life Assurance Company of Canada and operates in Hong Kong.

Source

• Since announcing its Corporate Value-Up Plan in 2025, Coway has been seeing tangible progress across revenue growth, shareholder returns, financial soundness and governance
• To date, the company has executed KRW 247.3 billion in shareholder returns, achieving the 40% return rate goal
• Starting in FY2026, Coway will prioritize cash dividends to secure high-dividend company status and tax benefits for shareholders
• Reporting an enhanced compliance rate on key governance indicators of 74%, Coway targets 93% by 2027

SEOUL, South Korea, Feb. 6, 2026 /PRNewswire/ — Coway Co., Ltd., the “Best Life Solution Company,” today announced an assessment of the implementation status of its Corporate Value-Up Plan, outlining concrete achievements to enhance shareholder value and detailing its mid- to long-term strategic roadmap.

Last year, Coway unveiled its Corporate Value-Up Plan, which includes the following key indicators to be achieved by 2027: achieving revenue exceeding KRW 5 trillion; maintaining a 40% shareholder return rate; managing a net debt-to-EBIT ratio of up to 2.5; and enhancing its governance frameworks.

Since announcing the plan, Coway has conducted several internal reviews of its implementation progress and has proactively prepared supplementary measures to enhance execution efficacy. This disclosure aims to transparently communicate an assessment of results to date, to convey future plans to shareholders and the market, and to reaffirm the credibility and positive impact of its value-up initiatives.

Early Progress Toward Revenue Goals: Accelerating the KRW 5 Trillion Roadmap

In 2025, Coway recorded KRW 4.96 trillion in revenue, a 15.2% year-over-year increase. This performance significantly outpaces the company’s targeted compound annual growth rate (CAGR) of 6.5%, placing Coway well ahead of schedule to exceed its KRW 5 trillion goal by 2027.

Coway sustained solid growth in 2025 through strengthened competitiveness in its domestic business and the continued expansion of its overseas operations. In the domestic market, steady growth in water purifier rental accounts served to reinforce the foundation of the company’s core business, while on the global front, revenue growth was driven by continual expansion at existing overseas subsidiaries, as well as rapid growth from newer entities.

This strong performance was fueled, in particular, by BEREX, Coway’s sleep and wellness brand, first launched in 2022 as part of Chairman Junhyuk Bang’s strategic vision to secure new growth engines. In 2025, BEREX generated KRW 719.9 billion in combined domestic and overseas revenue.

Alongside the launches of BEREX products to international markets and the expansion of product lineups across a variety of categories, in line with the Chairman’s strategy for global expansion, the contribution of overseas markets to Coway’s overall revenue increased to approximately 40% in 2025, further strengthening Coway’s presence on the global stage.

Delivering a 40% Shareholder Return Rate Through Balanced Execution

Coway successfully achieved a 40% total shareholder return rate in 2025, comprising KRW 247.3 billion. This was achieved through a balanced mix of KRW 137.3 billion in cash dividends and KRW 110.0 billion in treasury stock acquisitions. Notably, the company retired approximately 1.9 million treasury shares acquired in 2017 and 2024 in order to directly boost per-share value.

While maintaining the 40% return rate through 2027, Coway will prioritize cash dividends to satisfy “High-Dividend Company” requirements that enable the shareholders to benefit from separate taxation on dividend income. The company will also maintain a dividend payout ratio of at least 25% and increase the total dividend amount by more than 10% year-over-year. The remaining 15% of the return pool will be flexibly allocated between treasury stock purchases and additional cash dividends to maximize shareholder tax benefits and total yields.

Maintaining Financial Soundness and Stable Capital Structure Management

Alongside the expansion of growth investments and shareholder returns, Coway is working to manage its target capital structure in a manner that ensures financial stability. As of 2025, the company’s net debt-to-EBIT ratio stood at 2.1, and Coway plans to manage it up to 2.5 by 2027 through continued and consistent capital structure management.

In order to secure funds for growth investments, working capital and shareholder returns, Coway actively utilizes debt financing to enhance capital efficiency, all the while rigorously maintaining its credit rating risk so as to further strengthen long-term fiscal viability.

Strengthening Compliance Rates for Key Governance Indicators

Since first announcing its Corporate Value-Up Plan, Coway has reported an increase in its compliance rate on key governance indicators to 74%, a rise driven by an increase in the proportion of outside directors to 67% as well as the establishment of a Compensation Committee composed entirely of outside directors.

Coway has also outlined a mid- to long-term roadmap for its corporate governance advancement. In 2026, the company plans to establish an Internal Transaction Committee and a Senior Independent Director system to further enhance its corporate governance, and will also undertake amendments to its articles of incorporation in line with the recent revisions to South Korea’s Commercial Act. By 2027, Coway aims to reach a compliance rate on key governance indicators of 93% through measures such as the adoption of electronic voting and cumulative voting systems.

A Coway official said, “Since announcing our Corporate Value-Up Plan, we have delivered tangible results across our growth rate, shareholder returns and governance standards. Going forward, we will continue to monitor implementation of the plan closely using key indicators, and remain dedicated to a balanced approach that reinforces both investment in future growth engines and shareholder returns, thereby ensuring the steady enhancement of corporate value over the mid to long term.”

For additional details about Coway’s Corporate Value-Up Plan, please visit the company’s Investor Relations Page.

About Coway Co., Ltd.

Established in Korea in 1989, Coway, the “Best Life Solution Company,” is a leading home environment appliances company making people’s lives healthy and comfortable with innovative home appliances such as water purifiers, air purifiers, bidets, and mattresses. BEREX, the company’s sleep & wellness brand, aims to improve the quality of life through cutting-edge mattresses and massage chairs. Since being founded, Coway has become a leader in the home environment appliances industry, with intensive research, engineering, development, and customer service. The company has proven dedication to innovation with award-winning products, home health expertise, unrivaled market share, customer satisfaction, and brand recognition. Coway continues to innovate by diversifying product lines and accelerating overseas business in Malaysia, the USA, Thailand, China, Indonesia, Vietnam, and Europe, based on the business success in Korea. In 2025, the company launched Coway Life Solution, a premium elder care platform offering personalized care solutions tailored to different life stages. For more information, please visit http://www.coway.com/ or http://newsroom.coway.com.

Source: Coway Co., Ltd.

Source

MUMBAI, India, Feb. 6, 2026 /PRNewswire/ — Piramal Critical Care, Inc. (PCC), an overseas subsidiary of Piramal Pharma Limited, and Blue-Zone Technologies Ltd. (Blue-Zone) announced an agreement to collaborate on full lifecycle technology to capture and recycle waste anaesthetic gases.

By combining the innovative waste anaesthesia gas capture, collection, and processing technology developed by Blue-Zone, with the global manufacturing and marketing capabilities of Piramal, this collaboration will support customers’ efforts to minimize the environmental impact of volatile anaesthetics.  This collaboration will also help ensure that these essential products remain the primary method of providing general anaesthesia for patients around the world.

Pending regulatory approval in Europe of Blue-Zone’s Phoenix Deltasorb® waste anaesthetic gas capture system, Blue-Zone will offer these systems to PCC’s customers in Europe, initially in France and Germany. Blue-Zone will be responsible for all activities involving the supply and use of its systems in healthcare facilities. PCC will process captured waste anaesthetic gas using Blue-Zone’s technology to produce Sevoflurane USP for human use in Canada.

The parties anticipate that the scope of the waste anaesthetic gas capture, collection and recycling, and the marketing of Sevoflurane USP using waste anaesthetic gas, will expand into additional geographies. 

Jeff Hampton, President and COO Piramal Critical Care, commented:

“Piramal Critical Care is proud to partner with Blue-Zone on this innovative waste anaesthetic gas capture, collection, and recycling technology to help reduce waste and minimize environmental impact. By introducing gas capture technology, hospitals can choose the inhaled anaesthetic that best meets clinical needs while also supporting more sustainable healthcare goals.

Inhaled anaesthetics are vitally important medicines that enable essential treatment for patients around the world. As a leading global manufacturer of general anaesthesia products, Piramal Pharma is committed to supporting clinicians, hospitals, and health systems with solutions that balance clinical performance and environmental responsibility. Our focus is to ensure that patients continue to receive the critical care they need while advancing more sustainable approaches to anaesthesia.”

About Piramal Critical Care:

PCC is a global leader in anaesthesia, pain management and intrathecal therapy. PCC maintains a wide global footprint, delivering continuous supply to hospitals in more than 100 countries around the world. PCC’s product portfolio includes inhaled anaesthetics, intrathecal treatments for spasticity and pain management, plasma volume expanders, and a variety of other injectables and generics. PCC has strong manufacturing and process development capabilities with state-of-the-art manufacturing facilities in Bethlehem, PA, United States, Digwal, India, and Dahej, India with global regulatory accreditations and adherence to strict GMP regulations. In addition, PCC partners with leading pharmaceutical development and manufacturing organizations around the world.

For more information and updates, please visit: www.piramalcriticalcare.com

About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over the counter consumer and wellness products. In addition, one of PPL’s associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information visit: Piramal Pharma | LinkedIn

* Includes one facility via PPL’s minority investment in Yapan Bio.

For queries:

Madiha Vahid, Lead – Branding & Communications
Madiha.Vahid@piramal.com

Gagan Borana, Investor Relations & Enterprise Risk Management
Gagan.Borana@piramal.com

About Blue-Zone Technologies Ltd.

Blue-Zone, based in Ontario, Canada, is an innovative cleantech pharma business focused on the capture, recovery, and processing of waste anaesthetic gas (WAG). Our goal is to protect the environment and produce volatile anaesthetics. With strategic investors and leadership, an experienced and committed team, anaesthetic drug approvals in Canada, and business and technology partners around the world, Blue-Zone develops and markets equipment and processes to provide the full life cycle of volatile anaesthetics. Blue-Zone supports collection of WAG at healthcare facilities using volatile anaesthetics and conversion of the WAG into approved anaesthetic drugs.

For more information about Blue-Zone, please contact health@blue-zone.ca or visit www.blue-zone.com.

Source